Melanoma Clinical Trials

Find clinical trials for melanoma. Search for melanoma clinical trials in different cities and states across the United States.

Filter

Filter results

Results: 328

PF-08046054A Study of SGN-PDL1V in Advanced Solid Tumors

Recruiting

PHASE1

Sponsor:

Seagen Inc.

Location:

Birmingham AL, Sacramento CA, Iowa City IA, Detroit MIshow 8 more

Code:

NCT05208762

Conditions

Carcinoma, Non-Small-Cell Lung

Squamous Cell Carcinoma of the Head and Neck

Esophageal Squamous Cell Carcinoma

Ovarian Neoplasms

Melanoma

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

PF-08046054

pembrolizumab

NX-1607A Study of NX-1607 in Adults With Advanced Malignancies

Recruiting

PHASE1

Sponsor:

Nurix Therapeutics, Inc.

Location:

Los Angeles CA, San Francisco CA, Aurora CO, Chicago ILshow 5 more

Code:

NCT05107674

Conditions

Ovarian Cancer, Epithelial

Gastric Cancer

GastroEsophageal Junction (GEJ) Cancer

Head and Neck Squamous Cell Carcinoma

Metastatic or Unresectable Melanoma

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

NX-1607

Paclitaxel

IMM-1-104A Phase 1/2a Study of IMM-1-104 in Participants With Advanced or Metastatic Solid Tumors

Recruiting

PHASE1

PHASE2

Sponsor:

Immuneering Corporation

Location:

Scottsdale AZ, Duarte CA, San Diego CA, Santa Monica CAshow 15 more

Code:

NCT05585320

Conditions

Advanced Solid Tumor

Pancreatic Adenocarcinoma

Malignant Melanoma (Cutaneous)

Non-small Cell Lung Cancer (NSCLC)

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

IMM-1-104 Monotherapy (Treatment Group A)

IMM-1-104 + modified Gemcitabine/nab-Paclitaxel (Treatment Group B)

IMM-1-104 + modified FOLFIRINOX (Treatment Group C)

IMM-1-104 + dabrafenib (Treatment Group D)

IMM-1-104 + pembrolizumab (Treatment Group E)

IMA203 vs. Investigator's ChoiceSUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma

Recruiting

PHASE3

Sponsor:

Immatics US, Inc.

Location:

Scottsdale AZ, New Haven CT, Tampa FL, Boston MAshow 8 more

Code:

NCT06743126

Conditions

Melanoma, Cutaneous Malignant

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

IMA203

nivolumab plus relatlimab

lifileucel

nivolumab

pembrolizumab

SX-682 with PembrolizumabSX-682 Treatment in Subjects With Metastatic Melanoma Concurrently Treated With Pembrolizumab

Recruiting

PHASE1

Sponsor:

Syntrix Biosystems, Inc.

Location:

Miami FL, Boston MA, Rochester MN, Rochester NYshow 1 more

Code:

NCT03161431

Conditions

Melanoma Stage III

Melanoma Stage IV

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

SX-682

Pembrolizumab

Gallium PSMA-PET/CTA Study of 68Gallium PSMA-PET/CT Scans in People With Bladder Cancer or Skin Cancer

Recruiting

PHASE1

Sponsor:

Memorial Sloan Kettering Cancer Center

Location:

New York NY

Code:

NCT05562791

Conditions

Bladder Cancer

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

[68Ga]PSMA

PET/CT imaging

Fianlimab & CemiplimabA Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back After it Has Been Removed With Surgery

Recruiting

PHASE3

Sponsor:

Regeneron Pharmaceuticals

Location:

La Jolla CA, San Francisco CA, Santa Monica CA, Englewood COshow 25 more

Code:

NCT05608291

Conditions

Melanoma

Eligibility Criteria

Sex: All

Age: 12+

Healthy Volunteers: Not accepted

Interventions

Fianlimab

Cemiplimab

Pembrolizumab

Placebo

REGN10597A First-In Human (FIH) Trial to Find Out if REGN10597 is Safe and How Well it Works for Adult Participants With Advanced Solid Organ Malignancies

Recruiting

PHASE1

PHASE2

Sponsor:

Regeneron Pharmaceuticals

Location:

Los Angeles CA, San Francisco CA, North Haven CT, Chicago ILshow 6 more

Code:

NCT06413680

Conditions

Melanoma

Clear-Cell Renal-Cell Carcinoma (ccRCC)

Advanced Solid Tumors

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

REGN10597

IOV-4001A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer

Recruiting

PHASE1

PHASE2

Sponsor:

Iovance Biotherapeutics, Inc.

Location:

Los Angeles CA, Miami FL, Orlando FL, Tampa FLshow 6 more

Code:

NCT05361174

Conditions

Unresectable Melanoma

Metastatic Melanoma

Stage III Non-small Cell Lung Cancer

Stage IV Non-small Cell Lung Cancer

Eligibility Criteria

Sex: All

Age: 18 - 70

Healthy Volunteers: Not accepted

Interventions

IOV-4001

[225Ac]-FPI-1434A Phase 1/2 Study of [225Ac]-FPI-1434 Injection

Recruiting

PHASE1

PHASE2

Sponsor:

Fusion Pharmaceuticals Inc.

Location:

Duarte CA, Boston MA, Minneapolis MN, Buffalo NYshow 7 more

Code:

NCT03746431

Conditions

Advanced Solid Tumours

Endometrial Cancer

Cervical Cancer

Ovarian Cancer

Breast Cancer

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

[111In]-FPI-1547 Injection

[225Ac]-FPI-1434 Injection multi-dose

FPI-1175 Infusion

[225Ac]-FPI-1434 Injection single-dose